Adial Pharmaceuticals adds Wendy Young to board of directors

Adial

Adial

ADIL

0.00
  • Adial Pharmaceuticals named Wendy Young to its board as it integrates Azora Therapeutics.
  • Young brings 32 years in drug discovery and biopharma leadership, including senior vice president of small-molecule drug discovery at Genentech.
  • Azora co-founder Matt Davidson will join as chief development officer and a newly appointed director.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.